HIV Drugs Market Rising in United States | Fortune Business Insights
The global HIV drugs market is set to gain traction from the increasing development of antiretroviral therapy to make it a first long-acting injectable formulation and a long-acting suppression (ATLAS). Physicians often anticipate that the ATLAS regimen can efficiently improve the compliance rates and can be made available in the once-a-month dosage form. In January 2021, for instance, Evergreen Health bagged the U.S. FDA approval for Cabenuva. It is the first complete and injectable regimen for HIV-1 infected adults that can be registered once every month. As per a published report by Fortune Business Insights™, titled, “HIV Drugs Market, 2021-2028,” the market stood at USD 28.79 billion in 2020. It is projected to grow from USD 30.46 billion in 2021 to USD 45.58 billion in 2028 at a CAGR of 5.9% in the forecast period.
Get Sample PDF Brochure: https://www.fortunebusinessinsights.com/enquiry/sample/hiv-aids-drugs-market-101115
Merck Receives Approval from U.S. FDA for PIFELTRO
and DELSTRIGO
In September 2019, Merck announced that it received the U.S.
FDA approval for DELSTRIGO™ (as a complete regimen) and PIFELTRO™ (in
combination with other antiretroviral agents). These will be used in adult
patients for the treatment of HIV-1 infection. These
patients will have to be suppressed on a stable antiretroviral regimen with no
history of substitutions related to the resistance to both drugs and treatment
failures. As per one of the company officials, “These broadened indications
would help certain people with HIV-1 infection to move towards PIFELTRO and
DELSTRIGO from their current antiretroviral therapy by combining other
antiretroviral agents.” Such initiatives by reputed players would bolster the
demand for these drugs in the near future.
Increasing
Cases of HIV Infections to Boost Demand for HIV Drugs Worldwide
In developing regions, such as Africa, the cases of
HIV infections are surging rapidly. It is set to drive the HIV drugs market
growth. The World Health Organization (WHO) mentioned that in 2019, 1.7 million
new HIV-infected patients were reported, while 33.0 million people were living
with the infection globally. Besides, the Joint United Nations Programme on
HIV/AIDS (UNAIDS) stated that in 2019, there were approximately 5.8 million
HIV-infected individuals in Asia Pacific, 20.7 million people in Eastern and
Southern Africa, and 2.2 million people in Western & Central Europe and
North America. However, the ongoing COVID-19 pandemic has resulted in the
reduced demand for antiretroviral drugs, which, in turn, may hamper growth.
COVID-19
Pandemic: Declining Number of New Patient Prescriptions to Hamper Growth
The COVID-19 pandemic has severely
affected the import and export activities of healthcare products worldwide on
account of nationwide lockdowns and disturbances in supply chains. Besides, the
reduced number of new patient prescriptions in highly COVID-impacted areas has
further lowered the demand for antibiotic and antiretroviral HIV drugs. We are
providing elaborate reports to help you find the best solution to enhance your
businesses amid the pandemic.
Speak
To Our Analyst: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/hiv-aids-drugs-market-101115
About Us:
Fortune Business Insights™ delivers accurate data and innovative
corporate analysis, helping organizations of all sizes make appropriate
decisions. We tailor novel solutions for our clients, assisting them to address
various challenges distinct to their businesses. Our aim is to empower them
with holistic market intelligence, providing a granular overview of the market
they are operating in.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Comments
Post a Comment